Cargando…

Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin

OBJECTIVE: To report the case of a woman who presented for fertility preservation before breast cancer treatment who was found to be pregnant with an undesired pregnancy. DESIGN: Case report. SETTING: Single infertility practice. PATIENT: A 28-year-old woman with a new diagnosis of grade 3 invasive...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpinello, Olivia, Aserlind, Alexandra, Chang, Frank, Sagoskin, Arthur, Widra, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244282/
https://www.ncbi.nlm.nih.gov/pubmed/34223213
http://dx.doi.org/10.1016/j.xfre.2020.04.007
_version_ 1783715902765662208
author Carpinello, Olivia
Aserlind, Alexandra
Chang, Frank
Sagoskin, Arthur
Widra, Eric
author_facet Carpinello, Olivia
Aserlind, Alexandra
Chang, Frank
Sagoskin, Arthur
Widra, Eric
author_sort Carpinello, Olivia
collection PubMed
description OBJECTIVE: To report the case of a woman who presented for fertility preservation before breast cancer treatment who was found to be pregnant with an undesired pregnancy. DESIGN: Case report. SETTING: Single infertility practice. PATIENT: A 28-year-old woman with a new diagnosis of grade 3 invasive ductal carcinoma of the breast was planning to undergo oocyte cryopreservation and was found to be pregnant with an undesired pregnancy. She underwent a medical termination at a gestational age of 5 weeks 4 days. Neither the patient nor her oncology team wished to delay treatment more than was necessary. The physician and patient decided to initiate controlled ovarian hyperstimulation (COH) before her human chorionic gonadotropin (hCG) returned to normal. INTERVENTION(S): COH in the setting of a positive quantitative hCG. MAIN OUTCOME MEASURE(S): Number of metaphase II (MII) oocytes cryopreserved; doses of Gonal-F and Menopur; serum E(2), follicle-stimulating hormone, luteinizing hormone, hCG levels. RESULT(S): COH began 7 days after passing the products of conception. Baseline labs demonstrated hCG at 222 mIU/mL, follicle-stimulating hormone at <0.10 mIU/mL, luteinizing hormone at <1.10 mIU/mL, and E(2) at 147 pg/mL. She was started on an antagonist protocol with the use of 150 IU Gonal F and 75 IU Menopur. She was triggered on stimulation day 14 with 5,000 U hCG, and her peak E(2) was 5,924 pg/mL. She ultimately had 18 oocytes retrieved, 12 of which were MII, one MI, and five germinal vesicle. All were vitrified. CONCLUSION(S): COH can be achieved in the setting of low positive hCG levels with subsequent successful oocyte maturation. The threshold for hCG trigger to be ineffective in the setting of a positive hCG has yet to be determined.
format Online
Article
Text
id pubmed-8244282
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82442822021-07-02 Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin Carpinello, Olivia Aserlind, Alexandra Chang, Frank Sagoskin, Arthur Widra, Eric F S Rep Original Article OBJECTIVE: To report the case of a woman who presented for fertility preservation before breast cancer treatment who was found to be pregnant with an undesired pregnancy. DESIGN: Case report. SETTING: Single infertility practice. PATIENT: A 28-year-old woman with a new diagnosis of grade 3 invasive ductal carcinoma of the breast was planning to undergo oocyte cryopreservation and was found to be pregnant with an undesired pregnancy. She underwent a medical termination at a gestational age of 5 weeks 4 days. Neither the patient nor her oncology team wished to delay treatment more than was necessary. The physician and patient decided to initiate controlled ovarian hyperstimulation (COH) before her human chorionic gonadotropin (hCG) returned to normal. INTERVENTION(S): COH in the setting of a positive quantitative hCG. MAIN OUTCOME MEASURE(S): Number of metaphase II (MII) oocytes cryopreserved; doses of Gonal-F and Menopur; serum E(2), follicle-stimulating hormone, luteinizing hormone, hCG levels. RESULT(S): COH began 7 days after passing the products of conception. Baseline labs demonstrated hCG at 222 mIU/mL, follicle-stimulating hormone at <0.10 mIU/mL, luteinizing hormone at <1.10 mIU/mL, and E(2) at 147 pg/mL. She was started on an antagonist protocol with the use of 150 IU Gonal F and 75 IU Menopur. She was triggered on stimulation day 14 with 5,000 U hCG, and her peak E(2) was 5,924 pg/mL. She ultimately had 18 oocytes retrieved, 12 of which were MII, one MI, and five germinal vesicle. All were vitrified. CONCLUSION(S): COH can be achieved in the setting of low positive hCG levels with subsequent successful oocyte maturation. The threshold for hCG trigger to be ineffective in the setting of a positive hCG has yet to be determined. Elsevier 2020-06-30 /pmc/articles/PMC8244282/ /pubmed/34223213 http://dx.doi.org/10.1016/j.xfre.2020.04.007 Text en © 2020 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Carpinello, Olivia
Aserlind, Alexandra
Chang, Frank
Sagoskin, Arthur
Widra, Eric
Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin
title Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin
title_full Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin
title_fullStr Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin
title_full_unstemmed Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin
title_short Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin
title_sort fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244282/
https://www.ncbi.nlm.nih.gov/pubmed/34223213
http://dx.doi.org/10.1016/j.xfre.2020.04.007
work_keys_str_mv AT carpinelloolivia fertilitypreservationinanoncologypatientwhopresentedwithpositivehumanchorionicgonadotropin
AT aserlindalexandra fertilitypreservationinanoncologypatientwhopresentedwithpositivehumanchorionicgonadotropin
AT changfrank fertilitypreservationinanoncologypatientwhopresentedwithpositivehumanchorionicgonadotropin
AT sagoskinarthur fertilitypreservationinanoncologypatientwhopresentedwithpositivehumanchorionicgonadotropin
AT widraeric fertilitypreservationinanoncologypatientwhopresentedwithpositivehumanchorionicgonadotropin